Partnering
Contact
Contact Information
Join Us
EN
CN
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
Southeast Asia Business
News
Company News
Partner News
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Home
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
News
Company News
Partner News
Investors
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Partnering
Contact
Contact Information
Join Us
EN
CN
2022-07-08
Ranked in the list of Forbes on the “Best Enterprises Under a Billion”
Awarded the “Best Listed Company” by Ta Kung Pao
Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”
Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years and “Top 100 Enterprises in Tianjing Development Zone”
Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China
Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions